Alumis Inc. Connects with Investors This September
This September, Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company, is making headlines with a series of important investor conferences. Renowned for its development of oral therapies aimed at immune-mediated diseases, Alumis is dedicated to enhancing clinical outcomes for patients through precision medicine. The management team is excited to share valuable insights and updates regarding their innovative research and progress.
Upcoming Conferences
Alumis is scheduled to participate in several key events this September, where they will highlight their advancements:
Morgan Stanley 22nd Annual Global Healthcare Conference
On September 5, 2024, at 8:30 am ET, Alumis will take part in this event in New York. The agenda includes a fireside chat and one-on-one meetings with investors, providing a crucial opportunity for Alumis to connect with investors and discuss its strategic vision.
Wells Fargo Healthcare Conference
Alumis will attend this exclusive event in Boston on September 6, 2024, focusing on one-on-one meetings with investors. These discussions are anticipated to offer deeper insights into the company’s pipeline and ongoing initiatives.
Baird 2024 Global Healthcare Conference
Set for September 11, 2024, at 8:30 am ET in New York, this conference will feature a presentation from the Alumis team. They will discuss the company’s developmental programs, followed by individual meetings with investors. Additionally, attendees will have access to a recorded webcast replay available on the Investor Events page of the Alumis website for 90 days after the conference.
Cantor Fitzgerald Global Healthcare Conference
On September 17, 2024, at 10:55 am ET, Alumis will participate in this conference in New York. The event will include a fireside chat and one-on-one investor meetings. Live webcasts will be available, along with replay access for 90 days post-event.
Stifel 2024 Immunology and Inflammation Virtual Summit
Lastly, on September 18, 2024, at 10:00 am ET, Alumis will present at this virtual summit. With a focus on immunology and inflammation, this summit serves as an excellent platform to discuss the company’s innovative approaches and therapeutic solutions.
About Alumis Inc.
Alumis is at the forefront of advancements in the biopharmaceutical sector, utilizing its proprietary precision data analytics platform. The company is dedicated to developing a wide array of oral therapies aimed at significantly improving the quality of life for patients suffering from immune-mediated diseases. Their flagship product candidate, ESK-001, is a small molecule inhibitor targeting tyrosine kinase 2, currently being evaluated for the treatment of moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Additionally, Alumis is progressing with A-005, a novel compound that may have applications in neuroinflammatory and neurodegenerative conditions.
Frequently Asked Questions
What is Alumis Inc. known for?
Alumis Inc. specializes in developing oral therapies that take a precision approach to treat immune-mediated diseases.
When is Alumis participating in the Morgan Stanley conference?
Alumis will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 8:30 am ET.
What is ESK-001?
ESK-001 is Alumis’ leading product candidate, designed as a selective inhibitor of tyrosine kinase 2, and is currently being evaluated for treating plaque psoriasis and lupus.
Where can I find more information about Alumis’ events?
For additional details about Alumis’ conferences and presentations, you can visit the Investor Events page on their official website.
What role does precision medicine play in Alumis' approach?
Precision medicine is a core element of Alumis' development strategy, enabling tailored treatments that enhance clinical outcomes for patients with immune-mediated diseases.
